Turn Therapeutics Inc. (TTRX) Income Statement
TTRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTTRX revenue and net income
TTRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TTRX quarterly EPS vs estimates
Turn Therapeutics beat the analyst EPS estimate in 0 of the last 4 quarters. Next report: November 12, 2026 (estimate $-0.02).
TTRX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | $52,739 |
| Gross profit | — | — | — | −$52,739 |
| Research & development | $265,570 | $245,956 | $7,500 | — |
| Sales, general & admin | $5.6M | $1.6M | $2.3M | $4.2M |
| Total operating expenses | $5.9M | $1.8M | $2.3M | $4.2M |
| Operating income | −$5.9M | −$1.8M | −$2.3M | −$4.2M |
| Interest income | $29,583 | $28,709 | $15,882 | — |
| Interest expense | — | — | — | $85,383 |
| Income before taxes | −$3.2M | −$1.8M | −$2.3M | −$4.3M |
| Income taxes | — | — | — | $800 |
| Net income | −$3.2M | −$1.8M | −$2.3M | −$4.3M |
| EBITDA | −$3.1M | −$1.7M | −$2.2M | −$4.2M |
| EPS (diluted) | −$0.11 | −$0.07 | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Jun '24 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $14,531 | $14,451 | $14,155 | $13,679 | — | — |
| Gross profit | −$14,531 | −$14,451 | −$14,155 | −$13,679 | — | — |
| Research & development | $475,064 | $109,434 | $34,934 | $158,699 | $62,678 | $73,982 |
| Sales, general & admin | $1.2M | $1.1M | $2.2M | $1.8M | $1.3M | $286,198 |
| Total operating expenses | $1.6M | $1.2M | $2.2M | $1.9M | $1.4M | $360,180 |
| Operating income | −$1.6M | −$1.2M | −$2.2M | −$1.9M | −$1.4M | −$360,180 |
| Interest income | — | $49,679 | $14,175 | $5,111 | $5,134 | $8,244 |
| Interest expense | $241,359 | — | — | — | — | — |
| Income before taxes | −$5.8M | −$970,972 | $279,070 | −$1.9M | −$1.2M | −$351,936 |
| Net income | −$5.8M | −$970,972 | $279,070 | −$1.9M | −$1.2M | −$351,936 |
| EBITDA | −$1.6M | −$956,521 | $293,225 | −$1.9M | −$1.2M | −$351,936 |
| EPS (diluted) | −$0.07 | −$0.04 | $0.01 | −$0.07 | −$0.05 | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TTRX's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TTRX financial results
Turn Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $3.2 million. Diluted earnings per share came to −$0.11.
See the TTRX stock overview for the latest quote and news, or the TTRX chart for price history and technical indicators.
TTRX income statement FAQ
Does Turn Therapeutics have revenue?
Turn Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Turn Therapeutics profitable?
No. Turn Therapeutics reported a net loss of $3.2 million in fiscal 2025.
How much does Turn Therapeutics spend on research and development?
Turn Therapeutics spent $0.3 million on research and development in fiscal 2025.
What are Turn Therapeutics's earnings per share?
Turn Therapeutics earned $-0.11 per diluted share in fiscal 2025, compared with $-0.07 a year earlier.
When will Turn Therapeutics report its next earnings?
Turn Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Turn Therapeutics's fiscal year end?
Turn Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.